Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke - Trial NCT06137300
Access comprehensive clinical trial information for NCT06137300 through Pure Global AI's free database. This phase not specified trial is sponsored by Yi Yang and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 986 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Yi Yang
The First Hospital of Jilin University
Timeline & Enrollment
N/A
Dec 01, 2023
Dec 31, 2027
Primary Outcome
Proportion of patients with Modified Rankin Scale (mRS) Score 0-2 at 90 days
Summary
The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase
 treatment in patients with large artery atherosclerotic acute ischemic stroke.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06137300
Non-Device Trial